Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide

Novel agents such as thalidomide, lenalidomide, and bortezomib have been shown to possess potent activity against multiple myeloma. However, the treatment strategy for patients who acquired resistance to these agents has not been established. In addition to switching drug classes, intensified treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Shigeki, Oyake, Tatsuo, Murai, Kazunori, Ishida, Yoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625568/
https://www.ncbi.nlm.nih.gov/pubmed/23607005
http://dx.doi.org/10.1155/2013/651902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625568/
https://www.ncbi.nlm.nih.gov/pubmed/23607005
http://dx.doi.org/10.1155/2013/651902

Ejemplares similares